Compare WAFD & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAFD | BEAM |
|---|---|---|
| Founded | 1917 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | N/A | 2020 |
| Metric | WAFD | BEAM |
|---|---|---|
| Price | $33.31 | $26.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $31.40 | ★ $48.09 |
| AVG Volume (30 Days) | 834.0K | ★ 2.0M |
| Earning Date | 01-15-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | ★ 5.31 | N/A |
| EPS | ★ 2.63 | N/A |
| Revenue | ★ $717,732,000.00 | $55,701,000.00 |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $4.77 | $26.52 |
| P/E Ratio | $12.51 | ★ N/A |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $23.75 | $13.53 |
| 52 Week High | $36.41 | $35.25 |
| Indicator | WAFD | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 66.87 | 56.13 |
| Support Level | $32.70 | $25.86 |
| Resistance Level | $33.65 | $28.28 |
| Average True Range (ATR) | 0.68 | 1.63 |
| MACD | 0.07 | 0.25 |
| Stochastic Oscillator | 79.82 | 58.35 |
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.